sponsored
PatientsVille.com Logo

PatientsVille

Aropax Medical Research Studies

Up-to-date List of Aropax Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Aropax Medical Research Studies

Rank Status Study
1 Recruiting Effectiveness Study of Mirtazapine Combined With Paroxetine in Major Depressive Patients Without Early Improvement
Condition: Major Depression
Interventions: Drug: mirtazapine, paroxetine;   Drug: mirtazapine;   Drug: paroxetine 20mg QD
Outcome Measures: Change of 17-item Hamilton Depression Scale (HAMD-17) total score;   The proportion of subjects at endpoint with HAMD-17≤7;   The incidence and nature of overall adverse events;   The incidence and nature of drug-related adverse events;   The number of subject withdrawal due to adverse events during double-blind phase
2 Recruiting Interaction Between Paroxetine and Telaprevir
Conditions: Hepatitis C Infection;   Depression
Interventions: Drug: Paroxetine;   Drug: telaprevir
Outcome Measures: paroxetine area under the curve (AUC);   paroxetine Cmax and C24;   Number of Participants with Adverse Events as a Measure of Safety and Tolerability;   short term HCV RNA response;   telaprevir area under the curve (AUC)
3 Recruiting Study of Paroxetine and Fluconazole for the Treatment of HIV Associated Neurocognitive Disorder
Condition: HIV Associated Neurocognitive Disorder
Interventions: Drug: Fluconazole;   Drug: Paroxetine;   Drug: Paroxetine and Fluconazole;   Drug: Placebo
Outcome Measures: CSF lipid and protein markers of oxidative stress;   Neurocognitive performance;   Functional performance;   Magnetic resonance spectroscopy (MRS) and arterial spin labeling
4 Recruiting Vilazodone for Treatment of Geriatric Depression
Condition: Major Depressive Disorder
Interventions: Drug: Vilazodone; Viibryd;   Drug: Paroxetine; Paxil
Outcome Measures: Hamilton Depression Rating Scale (HDRS);   UKU Side-effect Profile;   Neurocognitive Measures;   Inflammatory Biomarkers
5 Not yet recruiting Lithium Versus Paroxetine in Major Depression
Condition: Major Depressive Disorder
Interventions: Drug: Lithium;   Drug: Paroxetine
Outcome Measures: Montgomery Asberg Depression Rating Scale (MADRS);   The Young Mania Rating Scale (YMRS);   The Clinical Global Impression (CGI);   The Columbia Suicide Classification Scale;   Barnes Akathisia Rating Scale (BARS);   Treatment -emergent symptom checklist and questionnaire
6 Recruiting Study to Evaluate the Sexual Functioning of Healthy Adults After Receiving Vilazodone, Paroxetine or Placebo
Condition: Healthy
Interventions: Drug: Vilazodone 20 mg;   Drug: Vilazodone 40 mg;   Drug: Paroxetine 20 mg;   Drug: Placebo
Outcome Measures: Change in Changes in Sexual Functioning Questionnaire (CSFQ) total score;   Proportion of subjects meeting criteria for sexual dysfunction.
7 Not yet recruiting Efficacy and Safety of Paroxetine Controlled Release for Major Depressive Disorder in Irritable Bowel Syndrome Patients
Condition: Depressive Disorder
Intervention: Drug: Paroxetine CR
Outcome Measures: HDRS-17;   HDRS-17 item 10;   CGI-I;   CGI-S;   WHOQOL;   IBSSS
8 Recruiting Influence of Pharmacogenetic Factors, Paroxetine and Clarithromycin on Pharmacokinetics of Clomiphene
Conditions: Anovulation;   Disorder Due Cytochrome P450 CYP2D6 Variant;   Cytochrome P450 CYP3A Enzyme Deficiency
Interventions: Drug: Clomiphene;   Drug: clomiphene and paroxetine;   Drug: clomiphene and clarithromycin
Outcome Measures: Area under the plasma concentration versus time curve (AUC)of clomiphene;   Peak Plasma Concentration (Cmax)of Clomiphene;   Clearance of Clomiphene;   Metabolomic;   Tmax of clomiphene;   Pharmacogenomics
9 Recruiting Paroxetine/Bupropion in Depression With Suicide Attempt or Thoughts: fMRI Study
Conditions: Depression;   Suicidal Ideation
Interventions: Drug: Paroxetine CR for Major Depressive Episode;   Drug: Bupropion XL for Major Depressive Episode
Outcome Measures: BOLD Signal;   Change in suicidal ideation (SSI score)
10 Unknown  Benefits of Switching Antidepressants Following Early Nonresponse
Condition: Depression
Interventions: Drug: Sertraline to Paroxetine;   Drug: Paroxetine to Sertraline
Outcome Measures: The Montgomery-Asberg Depression Rating Scale;   The Clinical Global Impression 2. The Quick Inventory of Depressive Symptomatology self-reported
11 Recruiting Efficacy of Exposure and Response Prevention(ERP) and SSRIs in Chinese OCD Patients
Conditions: Obsessive-Compulsive Disorder;   Anxiety Disorders;   Mental Disorders
Interventions: Drug: Fluoxetine;   Drug: Sertraline;   Drug: Paroxetine;   Drug: Citalopram;   Drug: Fluvoxamine;   Behavioral: Exposure and Response Prevention
Outcome Measures: The change of Yale-Brown Obsessive-Compulsive Scale score;   The change of Beck Depression Inventory(BDI-II) score;   The change of Beck Anxiety Inventory(BAI) score;   The change of Stress Perceived Questionnaire (PSS-10) score;   The change of Behavioral Inhibition/Behavioral Activation System Scales score;   The change of Barratt Impulsiveness Scale 11 (BIS-11) score;   The change of Obsessive Beliefs Questionnaire-44(OBQ-44) score;   The NEO-Five Factor Inventory-Revised (NEO-FFI-R);   The Early Trauma Inventory Self Report-Short Form(ETISR-SF)
12 Recruiting Brexpiprazole as an Additional Treatment to Paroxetine or Sertraline in Adult Patients Suffering From Post-traumatic Stress Disorder (PTSD)
Conditions: Post-traumatic Stress Disorder;   PTSD
Interventions: Drug: Placebo;   Drug: Brexpiprazole
Outcome Measures: Change from randomisation in PTSD symptoms using CAPS-2 total score;   Change from randomisation in global clinical impression using CGI-S score;   Change from randomisation in functioning using SDS score;   Safety;   Tolerability
13 Recruiting Predict Antidepressant Responsiveness Using Pharmacogenomics
Conditions: Depression;   Depressive Symptoms
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measure: Presences of each individual symptom of depression at 1,2,4,6,12 weeks
14 Recruiting Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients
Conditions: Depression;   Adverse Reaction to Drug
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measures: Antidepressant Response at 2,4,6 weeks A/E monitoring at 1,2,4,6 weeks;   Biological value at 0 and 6 weeks
15 Recruiting Development of A Technique to Predict Antidepressant Responsiveness in Depressive Patients
Conditions: Depression;   Continuous Antidepressant Abuse;   Adverse Reaction to Drug
Intervention: Drug: SSRI class antidepressant
Outcome Measures: Antidepressant Response at 2,4,6 weeks;   Biological value at 0 and 6 weeks
16 Recruiting Development of Pharmacogenomic Method to Predict Antidepressant Responsiveness
Conditions: Depression;   Antidepressant Drug Adverse Reaction
Interventions: Drug: SSRI class antidepressant;   Drug: non-SSRI class antidepressant
Outcome Measures: all pharmacogenetic and biological marker variables cause drug response;   all clinical cause drug response
17 Recruiting Magnetic Resonance Imaging Study of Cognitive-Behavior Therapy for Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: SSRI antidepressants;   Behavioral: Cognitive-Behavior Therapy
Outcome Measures: Hamilton Rating Scale for Depression (HAMD);   Magnetic Resonance Imaging
18 Unknown  Costs of Lost Productive Time Among Korean Workers With Panic Disorder and Effect of Treatment With Paroxetine Controlled Release
Condition: Panic Disorder
Intervention: Drug: Paroxetine CR
Outcome Measure:
19 Recruiting Algorithm Guided Treatment Strategies for Major Depressive Disorder
Condition: Major Depressive Disorder
Interventions: Drug: Escitalopram;   Drug: Mirtazapine;   Other: modified electroconvulsive therapy;   Other: repetitive transcranial magnetic stimulation;   Drug: Fluoxetine;   Drug: Citalopram;   Drug: Paroxetine;   Drug: Sertraline;   Drug: Fluvoxamine;   Drug: Venlafaxine;   Drug: Duloxetine;   Drug: Bupropion;   Drug: Trazodone
Outcome Measures: Remission defined as endpoint 17-item Hamilton Rating Scale for Depression (HRSD-17) total score ≤ 7;   Remission defined as endpoint the Quick Inventory of Depressive Symptomatology (16-item) (QIDS-SR16) total score ≤ 5;   Frequency and intensity of adverse events;   Quality of life
20 Unknown  Clinical Pharmacogenomics of Antidepressant Response
Condition: Major Depression
Intervention: Drug: Using Citalopram(drug) or Paroxetine(drug)
Outcome Measures: Using the following assessment instruments:;   Structured Clinical Interview for DSM-IV Disorders (SCID) at week baseline.;   Hamilton Depression Rating Scale (HAM-D) at week 1,2,4,6,8.;   Beck Depression Inventory (BDI) at week 1,2,4,6,8.;   Clinical Global Impression Scale (CGI) at week 1,2,4,6,8.;   Patient's Global Improvement Scale (PGI) at week 1,2,4,6,8.;   Treatment Emergent Symptoms Scale (TESS) at week 1,2,4,6,8.;   Arizona Sexual Experience Scale (ASEX) at week 1,2,4,6,8.

These studies may lead to new treatments and are adding insight into Aropax etiology and treatment.

A major focus of Aropax research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Aropax